Tags

Type your tag names separated by a space and hit enter

Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus.
Clin Chim Acta. 2015 Oct 23; 450:145-50.CC

Abstract

BACKGROUND

Although increased circulating levels of malondialdehyde-modified low-density lipoprotein (MDA-LDL) are associated with coronary artery disease (CAD), there is no direct evidence that increased MDA-LDL is a prognostic factor for CAD.

METHODS

Forty-two patients (20 diabetic and 22 non-diabetic patients) who underwent percutaneous coronary intervention (PCI) were enrolled, and their baseline MDA-LDL levels were determined by immunoassay. Follow-up coronary angiography was performed at 2 to 7 months post-PCI. The patients were then divided into 2 groups, with in-stent restenosis (ISR) (n=13) and without ISR (n=29), and the baseline MDA-LDL levels were compared. We also studied 34 diabetics with CAD for up to 57 months until the onset of the next coronary event.

RESULTS

In the diabetic patients, the mean MDA-LDL level was significantly higher in those with ISR than in those without ISR (151+/-61 vs. 90+/-26 U/l, p=0.010). A baseline MDA-LDL value of 110 U/l for differentiating between diabetics with and without ISR was defined as the cut-off value. Kaplan-Meier analysis demonstrated that a circulating MDA-LDL of ≥ 110 U/l correlated significantly with a higher prevalence of cardiac events than MDA-LDL <110 U/l (p=0.032).

CONCLUSIONS

Circulating MDA-LDL is a useful prognostic marker for future cardiac event in diabetic patients with CAD.

Authors+Show Affiliations

Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan. Electronic address: kotani@sekisui.com.Department of Internal Medicine, Chiba Cerebral and Cardiovascular Center, 575 Tsurumai, Ichihara, Chiba 290-0512, Japan; Department of Internal Medicine, Matsudo Municipal Hospital, 4005 Kamihongo, Matsudo, Chiba 271-8511, Japan.Department of Internal Medicine, Chiba Cerebral and Cardiovascular Center, 575 Tsurumai, Ichihara, Chiba 290-0512, Japan; Department of Internal Medicine, Matsudo Municipal Hospital, 4005 Kamihongo, Matsudo, Chiba 271-8511, Japan.Department of Internal Medicine, Chiba Cerebral and Cardiovascular Center, 575 Tsurumai, Ichihara, Chiba 290-0512, Japan.Department of Internal Medicine, Chiba Cerebral and Cardiovascular Center, 575 Tsurumai, Ichihara, Chiba 290-0512, Japan.Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, 564-1, Shimoshizu Sakura, Chiba 285-8741, Japan.Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 260-8670, Japan.Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26265234

Citation

Kotani, Kazuo, et al. "Investigation of MDA-LDL (malondialdehyde-modified Low-density Lipoprotein) as a Prognostic Marker for Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus." Clinica Chimica Acta; International Journal of Clinical Chemistry, vol. 450, 2015, pp. 145-50.
Kotani K, Tashiro J, Yamazaki K, et al. Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus. Clin Chim Acta. 2015;450:145-50.
Kotani, K., Tashiro, J., Yamazaki, K., Nakamura, Y., Miyazaki, A., Bujo, H., Saito, Y., Kanno, T., & Maekawa, M. (2015). Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus. Clinica Chimica Acta; International Journal of Clinical Chemistry, 450, 145-50. https://doi.org/10.1016/j.cca.2015.08.003
Kotani K, et al. Investigation of MDA-LDL (malondialdehyde-modified Low-density Lipoprotein) as a Prognostic Marker for Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus. Clin Chim Acta. 2015 Oct 23;450:145-50. PubMed PMID: 26265234.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus. AU - Kotani,Kazuo, AU - Tashiro,Jun, AU - Yamazaki,Kenya, AU - Nakamura,Yoshitake, AU - Miyazaki,Akira, AU - Bujo,Hideaki, AU - Saito,Yasushi, AU - Kanno,Takashi, AU - Maekawa,Masato, Y1 - 2015/08/08/ PY - 2015/01/16/received PY - 2015/08/01/revised PY - 2015/08/06/accepted PY - 2015/8/13/entrez PY - 2015/8/13/pubmed PY - 2016/4/26/medline KW - Cardiac event KW - Diabetes mellitus KW - Malondialdehyde-modified LDL KW - Oxidized LDL KW - Prognostic marker KW - Restenosis SP - 145 EP - 50 JF - Clinica chimica acta; international journal of clinical chemistry JO - Clin. Chim. Acta VL - 450 N2 - BACKGROUND: Although increased circulating levels of malondialdehyde-modified low-density lipoprotein (MDA-LDL) are associated with coronary artery disease (CAD), there is no direct evidence that increased MDA-LDL is a prognostic factor for CAD. METHODS: Forty-two patients (20 diabetic and 22 non-diabetic patients) who underwent percutaneous coronary intervention (PCI) were enrolled, and their baseline MDA-LDL levels were determined by immunoassay. Follow-up coronary angiography was performed at 2 to 7 months post-PCI. The patients were then divided into 2 groups, with in-stent restenosis (ISR) (n=13) and without ISR (n=29), and the baseline MDA-LDL levels were compared. We also studied 34 diabetics with CAD for up to 57 months until the onset of the next coronary event. RESULTS: In the diabetic patients, the mean MDA-LDL level was significantly higher in those with ISR than in those without ISR (151+/-61 vs. 90+/-26 U/l, p=0.010). A baseline MDA-LDL value of 110 U/l for differentiating between diabetics with and without ISR was defined as the cut-off value. Kaplan-Meier analysis demonstrated that a circulating MDA-LDL of ≥ 110 U/l correlated significantly with a higher prevalence of cardiac events than MDA-LDL <110 U/l (p=0.032). CONCLUSIONS: Circulating MDA-LDL is a useful prognostic marker for future cardiac event in diabetic patients with CAD. SN - 1873-3492 UR - https://www.unboundmedicine.com/medline/citation/26265234/Investigation_of_MDA_LDL__malondialdehyde_modified_low_density_lipoprotein__as_a_prognostic_marker_for_coronary_artery_disease_in_patients_with_type_2_diabetes_mellitus_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-8981(15)00374-5 DB - PRIME DP - Unbound Medicine ER -